Medicare to weigh nationwide coverage rules for Biogen Alzheimer's drug

Medicare to weigh nationwide coverage rules for Biogen Alzheimer's drug

Source: 
BioPharma Dive
snippet: 

The Centers for Medicare and Medicaid Services will formally consider whether to adopt nationwide rules for coverage of Biogen's new Alzheimer's drug Aduhelm, announcing Monday the opening of a determination process that could shape how millions of Americans are able to access the controversial treatment.